FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir
The FDA has accepted the New Drug Application (NDA) for IDVYNSO, which includes doravirine and islatravir.
Asset / Drug
Drug and asset intelligence for IDVYNSO with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Merck has entered an agreement with the ADAP Crisis Task Force to improve access to IDVYNSO™ for individuals living with HIV.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.